An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK)
- 31 July 2007
- journal article
- research article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 43 (11), 1687-1693
- https://doi.org/10.1016/j.ejca.2007.05.001
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the USCancer, 2007
- Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trialBritish Journal of Cancer, 2006
- CN1 COST-EFFECTIVENESS ANALYSIS OF OXALIPLATIN/5-FU/LV IN ADJUVANT TREATMENT OF STAGE III COLON CANCER IN THE UK AND GERMANYValue in Health, 2005
- Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon CancerNew England Journal of Medicine, 2004
- Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?Journal of Clinical Oncology, 2004
- Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysisHealth Economics, 2004
- Intensity of chemotherapy-induced emesis and overall survival as determinants of a global utility scoreSupportive Care in Cancer, 2002
- Quality of life in survivors of colorectal carcinomaCancer, 2000
- A Cost-Utility Analysis of Second-Line Chemotherapy in Metastatic Breast CancerPharmacoEconomics, 1996
- A cost utility analysis of treatment options for gallstone disease: Methodological issues and resultsHealth Economics, 1994